Emerging Infectious Diseases (Mar 2014)

Use of Drug-Susceptibility Testing for Management of Drug-Resistant Tuberculosis, Thailand, 2004–2008

  • Eugene Lam,
  • Sriprapa Nateniyom,
  • Sara Whitehead,
  • Amornrat Anuwatnonthakate,
  • Patama Monkongdee,
  • Apiratee Kanphukiew,
  • Jiraphan Inyaphong,
  • Wanlaya Sitti,
  • Navarat Chiengsorn,
  • Saiyud Moolphate,
  • Suporn Kavinum,
  • Narin Suriyon,
  • Pranom Limsomboon,
  • Junya Danyutapolchai,
  • Chalinthorn Sinthuwattanawibool,
  • Laura Jean Podewils

DOI
https://doi.org/10.3201/eid2003.130951
Journal volume & issue
Vol. 20, no. 3
pp. 408 – 416

Abstract

Read online

In 2004, routine use of culture and drug-susceptibility testing (DST) was implemented for persons in 5 Thailand provinces with a diagnosis of tuberculosis (TB). To determine if DST results were being used to guide treatment, we conducted a retrospective chart review for patients with rifampin-resistant or multidrug-resistant (MDR) TB during 2004–2008. A total of 208 patients were identified. Median time from clinical sample collection to physician review of DST results was 114 days. Only 5.8% of patients with MDR TB were empirically prescribed an appropriate regimen; an additional 31.3% received an appropriate regimen after DST results were reviewed. Most patients with rifampin -resistant or MDR TB had successful treatment outcomes. Patients with HIV co-infection and patients who were unmarried or had received category II treatment before DST results were reviewed had less successful outcomes. Overall, review of available DST results was delayed, and results were rarely used to improve treatment. Download MP3 Length: 1:33

Keywords